Indian Council of Medical Research COVID-19 Vaccine
Technical Data
| Date of Issue | January 16, 2022 |
|---|---|
| Denomination | Rs. 5 |
| Quantity | 301,920 |
| Perforation | 14 |
| Printer | Security Printing Press, Hyderabad |
| Printing Process | Wet Offset |
| Watermark | No Watermark |
| Colors | Multicolor |
| Credit (Designed By) | Sh. Brahm Prakash |
| Catalog Codes |
Michel IN 3758 Yvert et Tellier IN 3437 Stanley Gibbons IN 3799 |
| Themes | Diseases | Medical Science |
Commemorative Postage Stamp on COVAXIN – India’s First Indigenous COVID-19 Vaccine
In March 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic, marking the beginning of one of the biggest public health challenges in modern history. With lives disrupted worldwide, the development of a safe and effective vaccine emerged as the most powerful tool to curb transmission and save lives.
India rose to this challenge with resilience and innovation. The journey of COVAXIN, India’s first indigenous COVID-19 vaccine, began in April 2020 after scientists at the Indian Council of Medical Research (ICMR)–National Institute of Virology (NIV), Pune successfully isolated the SARS-CoV-2 virus strain. This strain was then transferred to Bharat Biotech International Ltd (BBIL), a Hyderabad-based company, which embarked on the mission to create a home-grown vaccine in record time.
The Making of COVAXIN
Through rigorous pre-clinical studies and human clinical trials across three phases, two promising formulations were identified. Trials conducted at 25 centers with over 25,800 participants reported an efficacy rate of 77.8% against symptomatic COVID-19, establishing COVAXIN’s strong safety and immunogenicity profile.
Even as new variants like Alpha, Beta, Delta, and others emerged, studies by ICMR-NIV confirmed COVAXIN’s effectiveness against them. This scientific rigor led to 17 research publications in internationally acclaimed journals, solidifying its reputation among the world’s leading vaccines.
A Global Recognition
On 3rd November 2021, COVAXIN became the eighth vaccine worldwide to receive the WHO Emergency Use Listing (EUL), a milestone that placed India firmly on the global scientific map. Achieving this feat within 10 months was a testament to the spirit of Atmanirbhar Bharat (Self-Reliant India) and the dedication of Indian scientists, healthcare workers, and industry leaders.
By the time India celebrated its 75th year of independence, 75% of Indians had been vaccinated, a remarkable public health achievement powered in part by COVAXIN.
Honoring a Milestone with Philately
To celebrate this landmark in India’s scientific and healthcare history, the Department of Posts issued a Commemorative Postage Stamp on COVAXIN. More than just a token of recognition, this stamp is a heartfelt tribute to the tireless efforts of healthcare workers, researchers, and industry partners who stood at the frontlines of the pandemic.
This COVAXIN commemorative stamp not only honors a scientific breakthrough but also symbolizes India’s resilience, innovation, and contribution to the global fight against COVID-19. For philatelists, it represents a unique blend of history, science, and national pride.
First Day Cover
